ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study
3rd October 2024 Uncategorised 0
Largest real-world study demonstrates significant survival advantage

More: ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study
Source: News
